Filtered By:
Education: Academia
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1079 results found since Jan 2013.
Initial versus early switch to targeted therapy during first-line treatment among patients with biomarker-positive advanced or metastatic non-small cell lung cancer in the United States
CONCLUSION: In both unadjusted and adjusted analyses, there were no differences in the clinical outcomes observed among patients with a/mNSCLC in this study. This study found that initiating chemotherapy with an early switch to targeted therapy (within 56 days) of receiving biomarker positive results may be an acceptable strategy for a patient for whom immediate care is needed.PMID:37717466 | DOI:10.1016/j.ctarc.2023.100761
Source: Cell Research - September 17, 2023 Category: Cytology Authors: Lisa M Hess Patrick Peterson Tomoko Sugihara Naleen Raj Bhandari Peter M Krein Anthony Sireci Source Type: research
Impact of Successful Implementation of an Enhanced Recovery After Surgery Protocol for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
CONCLUSIONS: Despite the heterogeneity of CRS/HIPEC operations, implementing an ERAS protocol for our patients was feasible and resulted in postoperative outcomes and adherence comparable with that of other major abdominal surgeries. This supports the potential for success in ERAS programs for CRS/HIPEC patients.PMID:37684372 | DOI:10.1245/s10434-023-14222-8
Source: Ann Oncol - September 8, 2023 Category: Cancer & Oncology Authors: Beatrice J Sun Tiffany M Yue Nova Xu Cedar Fowler Byrne Lee Source Type: research
Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study
CONCLUSIONS: Delayed treatment approaching 2 months was observed in 10% of the population. The rising temporal trend in TTT may be attributed to the increasing shift toward neoadjuvant CT/RT in early-stage PDAC and/or the increasing use of tissue biopsy prior to surgery.PMID:37624518 | DOI:10.1245/s10434-023-14221-9
Source: Ann Oncol - August 25, 2023 Category: Cancer & Oncology Authors: Kavin Sugumar Jonathan J Hue Shreya Gupta Mohamedraed Elshami Luke D Rothermel Lee M Ocuin John B Ammori Jeffrey M Hardacre Jordan M Winter Source Type: research
“Chemobrain” in childhood cancer survivors—the impact on social, academic, and daily living skills: a qualitative systematic review
ConclusionThis review highlights two important considerations: (1) the lived experiences of pediatric childhood cancer survivors guiding where future interventions should be targeted, and (2) a need to perform more qualitative research studies in this area, as well as to improve the quality of reporting among the existing literature, given that this is a current gap in the field.
Source: Supportive Care in Cancer - August 22, 2023 Category: Cancer & Oncology Source Type: research
Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
CONCLUSIONS: Early treatment period CRP and LDH levels were significant predictors of OS in patients with NSCLC undergoing immunotherapy.PMID:37577328 | PMC:PMC10413036 | DOI:10.21037/tlcr-23-7
Source: Cell Research - August 14, 2023 Category: Cytology Authors: MinDong Sung Won Seok Jang Hae Reong Kim Ji Ae Park Sun Min Lim Hye Ryun Kim Byoung Chul Cho Yu Rang Park Min Hee Hong Source Type: research
Nanotechnology-empowered strategies in treatment of skin cancer
This article also provides a summary of the various nanotechnology based combinatorial therapy available for skin cancer with their recent advances. This review also focuses on current status of clinical trials of such therapies.PMID:37451568 | DOI:10.1016/j.envres.2023.116649
Source: Cell Research - July 14, 2023 Category: Cytology Authors: Jyoti Chandra Nazeer Hasan Nazim Nasir Shadma Wahab Punniyakoti Veeraveedu Thanikachalama Amirhossein Sahebkar Farhan Jalees Ahmad Prashant Kesharwani Source Type: research
Physicians' Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care
CONCLUSION: This study demonstrates that physicians conceptualize the use of biomarkers for treatment optimization in successive levels. This hierarchy can be used to guide trialists in the development of novel biomarkers and design of future trials.PMID:37405703 | DOI:10.1093/oncolo/oyad198
Source: The Oncologist - July 5, 2023 Category: Cancer & Oncology Authors: Halle H Thannickal Noon Eltoum Nicole L Henderson Lauren P Wallner Lynne I Wagner Antonio C Wolff Gabrielle B Rocque Source Type: research
Initial presentation of the Pentafecta score as a quality instrument for outcome evaluation of primary surgical treatment in patients with penile cancer
CONCLUSION: Based on a moderated voting process among international PECa experts, a Pentafecta score was developed as a quality assurance instrument for primary surgical treatment, which now needs to be validated using patient-relevant and patient-reported endpoints.PMID:37339668 | DOI:10.1055/a-2065-8256
Source: Aktuelle Urologie - June 20, 2023 Category: Urology & Nephrology Authors: Matthias May Steffen Lebentrau Nick Watkin Maarten Albersen Chris Protzel Jad Chahoud Oscar R Brouwer Curtis A Pettaway Lance C Pagliaro Andrea Necchi Oliver W Hakenberg Ben Ayres Philippe E Spiess Source Type: research
